Mark November

ENDOSURE, INC. was founded based on a new approach to empower physicians with the tools they need for earlier, more accurate endometriosis diagnosis. To that end, we proudly offer the ENDOSURE TEST, the first and only Tier-1 diagnostic test for endometriosis. Since its introduction in 2022, this groundbreaking clinical support tool has already begun to shift the entire paradigm in how medical providers detect and treat endometriosis. The ENDOSURE TEST meets all major requirements of a Tier-1 diagnostic test, offering critical advantages: 🔹️ Low cost 🔹️ Easy-to-use 🔹️ Non-invasive 🔹️ Rapid results (30 minutes) 🔹️ Highly accurate (surgically verified) 🔹️ No population-related use restriction (detects disease in patients of any age, at any stage, anywhere in the anatomy) The ENDOSURE TEST is actively being used in many gynecology practices around the world, equipping medical providers with the means to detect endometriosis at its earliest stages and offer targeted, personalized therapy to their patients. At ENDOSURE, INC., we are committed to a future in endometriosis care where timely diagnosis is no longer a barrier to effective disease management, and no woman must wait nearly a decade for a definitive diagnosis.

Sepsim is a breakthrough biotech company developing a novel drug to combat Sepsis and MRSA—two of the deadliest threats in modern medicine. In preclinical animal trials, the results were nothing short of extraordinary: 100% survival in treated subjects, compared to 100% mortality in untreated controls. Our mission is clear and urgent: to solve Sepsis, a condition that claims millions of lives each year with limited effective treatments available. At Sepsim, we believe the cure starts here.

BrilliSkin is revolutionizing access to dermatologic care with a fast, affordable, and inclusive teledermatology platform. Users can simply snap a photo of their skin concern and connect with a board-certified dermatologist within 24 hours for about 10% of the cost of a traditional visit. With multilingual support and a focus on underserved communities, BrilliSkin breaks down the barriers of geography, cost, and language to make expert skincare accessible to everyone. Were on a mission to make skin health a right, not a privilege.

Diagnostic Ventures is a company focused on creating novel diagnostic medical technologies. Annually, sepsis affects 50 million people worldwide, with over 11 million deaths. Our company has a patented process that uses blood from a patient presenting with sepsis symptoms and produces results within 1 hour which identifies the most dangerous antimicrobial resistant genes present in bacteria that cause bloodstream infections. Our Rapid Sepsis test will help save lives, by quickly identifying patients who have this type of infection and providing doctors the tools to quickly prescribe the right antibiotics for sepsis infections.

Early detection of breast cancer saves lives. We are developing a tool to help women to know if they need a mammogram.

Welcome to Zeglass, where innovation meets sustainability in the world of dynamic glass offerings. Our cutting-edge Kinetic Glass technology represents the forefront of green tech in architectural design, offering dynamic optical solutions that adapt to environmental conditions and user needs. At Zeglass, we are committed to transforming spaces with glass that not only changes in transparency but also enhances energy efficiency, comfort, and aesthetic appeal. Our products embody the fusion of form and function, tailored to meet the evolving demands of modern architecture.

Smart Glass Labs | Steering the Future with Kinetic Glass | Engage with Us | Follow for the Latest in Glass Tech | Be the First to Witness our Sustainability Breakthroughs . Introducing Kinetic Glass by Smart Glass Labs – Experience our award-winning, innovative glass technology that revolutionizes spaces, transforming them into secure, sustainable, and future-ready havens. The versatile Kinetic Glass, provides tunable privacy, adjustable light transmission, and infrared control, elevating the aesthetics and functionality of both residential and commercial environments. With state-of-the-art electronics, optics, and characterization equipment, were proud to offer top-tier products to industry leaders, helping you elevate your glass applications and embrace a brighter, more sustainable future. As pioneers in the dynamic glazing industry, Smart Glass Labs is dedicated to providing comprehensive support for your research and development projects. Our custom tools and software, tailored for the glazing industry, are available to customers, contractors, builders, tenants, and manufacturers, ensuring you have everything needed to propel your project to success. At Smart Glass Labs, were on a mission to transform spaces with Kinetic Glass positively and sustainably. Connect with us today to explore how we can help unlock your projects full potential. Lets join forces to create a brighter, greener, and more innovative future together! #SmartGlassLabs #KineticGlass #Innovation #Sustainability #DynamicGlazing #GreenTech #SmartLiving #FutureReady #EcoFriendly #TransformSpaces #BuildingMaterials #SmartGlassTechnology

SeeMedX is revolutionizing the noninvasive heart monitoring space with its patented technology that can save lives and improve patient outcomes. The team has a proven track record of success in both the medical and business industries, with experience in bringing products to market and scaling businesses.

Devorto is building an aircraft that never has to land. Solar-powered aircraft provide better capabilities than satellite networks, but for the cost and logistics of operating an unmanned system. While existing high-altitude pseudo-satellite (HAPS) attempts can only operate under ideal solar conditions, Devorto is developing a novel architecture called the Tethered Uni-Rotor Network (TURN). Designed and patented by a former NASA engineer, and with R&D funding from NASA and the US Air Force, this unconventional approach is 10X more efficient than fixed-wing without sacrificing vertical takeoff. Persistent flight within the stratosphere opens the doors to global Internet connectivity, broadband speed telecom relay hubs, and unprecedented environmental/weather monitoring capabilities.

Eliaz Therapeutics (ETI), founded by Dr. Isaac Eliaz, focuses on harnessing his extensive expertise in Galectin-3 and Apheresis technology to create a cutting-edge therapeutic Apheresis device. This device aims to remove Galectin-3 from the bloodstream, which plays a pivotal role in various severe health conditions, particularly in Sepsis. Galectin-3 is linked to the exacerbation of inflammatory responses and immune dysregulation, including cytokine storms, which are critical factors in the progression and severity of sepsis. The primary application of this technology is targeted at treating sepsis and its common complication, sepsis-induced Acute Kidney Injury (SA-AKI). Sepsis is a life-threatening response to infection that can lead to tissue damage, organ failure, and death. In the United States alone, sepsis leads to millions of hospitalizations each year, with a significant number of these cases progressing to AKI. This condition complicates the course of sepsis by impairing kidney function, potentially necessitating intensive treatments like dialysis or kidney transplantation. Currently, there are no approved treatments that effectively prevent, alleviate, or expedite recovery from sepsis and its associated AKI. ETIs XGAL3 apheresis technology offers a potential breakthrough in sepsis treatment, aiming to improve patient management and outcomes dramatically, and offering hope for saving hundreds of thousands of lives each year.

If you work in wastewater treatment, you are familiar with one or more of the following issues: • Buildups from low flows and Fats, Oils, and Grease (FOG) causing clogs and Sanitary System Overflow (SS0) • Pungent and toxic odors resulting in resident complaints • Aeration’s energy inefficiency and the toll hydrogen sulfide gas (H2S) takes on equipment • Frequent, costly capital expenditure (CAPEX) upgrades • Permit restrictions and capacity limits conflicting with community expansion and development • Increasing operating expenses (OPEX) for routine procedures, including biosolid processing and disposal Bioaugmentation has been an industry standard “solution” to these problems for years. If you have tried it in the past with less than stellar results, you know the traditional, one-size-fits-all approach is not always sufficient. But today’s technology can achieve better results at lower costs. EnBiorganic Technologies has real, revolutionary solutions for wastewater treatment challenges. Our disruptive, patent-pending proprietary technology custom grows live bacteria — in active and adapted states — for each specific wastewater environment. Our EBS-Di system is compact, compatible with existing infrastructure, environmentally beneficial, and requires no additional work on the part of wastewater treatment personnel — all without adding to CAPEX or OPEX. In one performance trial, a wastewater treatment plant (WWTP) decreased a 40-year buildup of sludge in its lagoon by 67.5% — in only 10 days. To learn more about the technology that is turning the wastewater treatment industry upside down, visit EnBiorganic Technologies at enbiorganic.com today.

AI-Powered Precision Spraying. Targeted spraying at the plant level using AI + sensors. Cuts chemical use by up to 90%, saving costs and reducing waste. Improves soil health, crop quality, and compliance with regulations

ENDOSURE, INC. was founded based on a new approach to empower physicians with the tools they need for earlier, more accurate endometriosis diagnosis. To that end, we proudly offer the ENDOSURE TEST, the first and only Tier-1 diagnostic test for endometriosis. Since its introduction in 2022, this groundbreaking clinical support tool has already begun to shift the entire paradigm in how medical providers detect and treat endometriosis. The ENDOSURE TEST meets all major requirements of a Tier-1 diagnostic test, offering critical advantages: 🔹️ Low cost 🔹️ Easy-to-use 🔹️ Non-invasive 🔹️ Rapid results (30 minutes) 🔹️ Highly accurate (surgically verified) 🔹️ No population-related use restriction (detects disease in patients of any age, at any stage, anywhere in the anatomy) The ENDOSURE TEST is actively being used in many gynecology practices around the world, equipping medical providers with the means to detect endometriosis at its earliest stages and offer targeted, personalized therapy to their patients. At ENDOSURE, INC., we are committed to a future in endometriosis care where timely diagnosis is no longer a barrier to effective disease management, and no woman must wait nearly a decade for a definitive diagnosis.